Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jean-François Formela
AddedMar 31, 2024
UpdatedMay 31, 2026
Jean-François Formela

Jean-François Formela

Board Member, Korro Bio

Crunchbase

Jean-François Formela's Career

Korro Bio
Korro Bio

Cambridge, MA, US

Board Member· Board
Spero Therapeutics
Spero Therapeutics

Cambridge, MA, US

Board Member· Board
Intellia Therapeutics
Intellia Therapeutics

Cambridge, MA, US

Board Member· Board
Arteaus Therapeutics
Arteaus Therapeutics

Cambridge, MA, US

Co-Founder
Triplet Therapeutics
Triplet Therapeutics

Cambridge, MA, US

Board Member· Board
Navitor Pharmaceuticals
Navitor Pharmaceuticals

Cambridge, MA, US

Board Member· Board
Archemix
Archemix

Cambridge, MA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jean-François Formela's Career

Korro Bio
Korro Bio
Public$207.5M992018Cambridge, MA, US
Board Member· Board

Recent news

9 startups that stood out on YC Demo Day 2TechCrunch · 2024

Leadership at Korro Bio

Josh RosenthalJosh RosenthalCo-Founder
Hannah H ChangHannah H ChangBoard Member
Andrew FraleyAndrew FraleyBoard Member
Ram AiyarRam AiyarBoard Member
Spero Therapeutics
Spero Therapeutics
Public$443.6M352013Cambridge, MA, US
Board Member· Board

Leadership at Spero Therapeutics

Sath ShuklaSath ShuklaBoard Member
Ankit MahadeviaAnkit MahadeviaBoard Member
Kathleen TregoningKathleen TregoningBoard Member
Patrick VinkPatrick VinkBoard Member
Milind DeshpandeMilind DeshpandeBoard Member
Casper BreumCasper BreumBoard Member
Intellia Therapeutics
Intellia Therapeutics
Public$1.2B5982014Cambridge, MA, US
Board Member· Board

Leadership at Intellia Therapeutics

Nessan BerminghamNessan BerminghamCo-Founder
Rodolphe BarrangouRodolphe BarrangouCo-Founder
Luciano MarraffiniLuciano MarraffiniCo-Founder
Andy MayAndy MayCo-Founder
Rachel HaurwitzRachel HaurwitzCo-Founder
Caroline DorsaCaroline DorsaBoard Member
Arteaus Therapeutics
Arteaus Therapeutics
Acquired$30M02011Cambridge, MA, US
Co-Founder

Leadership at Arteaus Therapeutics

Scott ChappellScott ChappellCo-Founder

Similar to Arteaus Therapeutics

Arete TherapeuticsArete TherapeuticsHayward, CA, USDrug Developmentest. 2003Arete TherapeuticsHayward, CA, US · est. 2003

Arete Therapeutics Inc., a US biotech firm, innovates novel drugs for diabetes, hypertension, and inflammation.

Public · $51.7M30
Aristea TherapeuticsAristea TherapeuticsSan Diego, CA, USDrugsest. 2018Aristea TherapeuticsSan Diego, CA, US · est. 2018

Aristea Therapeutics: Developing novel drugs for autoimmune and inflammatory diseases.

Series B · $117.6M75
Artielle ImmunoTherapeuticsArtielle ImmunoTherapeuticsSan Mateo, CA, USDrug Developmentest. 2004Artielle ImmunoTherapeuticsSan Mateo, CA, US · est. 2004

Artielle ImmunoTherapeutics: A biotech firm innovating drugs for autoimmune diseases treatment.

Angel · $11.2M8
Arcuate TherapeuticsArcuate TherapeuticsBoston, MA, USPharmaceuticalsest. 2019Arcuate TherapeuticsBoston, MA, US · est. 2019

Boston-based pharmaceutical innovator, Arcuate Therapeutics, offers stealth healthcare solutions.

Series A · $5M5
Triplet Therapeutics
Triplet Therapeutics
Series A$59M362019Cambridge, MA, US
Board Member· Board
Navitor Pharmaceuticals
Navitor Pharmaceuticals
Series B$98.2M362010Cambridge, MA, US
Board Member· Board

Leadership at Navitor Pharmaceuticals

Alan CraneAlan CraneBoard Member
George P. VlasukGeorge P. VlasukBoard Member
Vinzenz PloererVinzenz PloererBoard Member
Paul A. FriedmanPaul A. FriedmanBoard Member
Marian NakadaMarian NakadaBoard Member
Thomas E HughesThomas E HughesBoard Member
Archemix
Archemix
Public$101.8M752001Cambridge, MA, US
Founder

Leadership at Archemix

John MaraganoreJohn MaraganoreBoard Member
Bob SteinBob SteinBoard Member
Mike RossMike RossBoard Member

Similar to Archemix

Guardian TherapeuticsGuardian TherapeuticsLexington, MA, USTherapeuticsest. 2017Guardian TherapeuticsLexington, MA, US · est. 2017

Guardian Therapeutics, pioneering the limitless potential of aptamer therapeutics.

Series B · $30M75
Arch TherapeuticsArch TherapeuticsFramingham, MA, USMedical Devicesest. 2009Arch TherapeuticsFramingham, MA, US · est. 2009

Arch Therapeutics: Innovating therapeutic solutions with peptide polymers to control bleeding.

Public · $27M7
KemiaKemiaSan Diego, CA, USPharmaceuticalsest. 2001KemiaSan Diego, CA, US · est. 2001

Discovering therapeutics for inflammation. Serving US healthcare.

Series C · $100M30
OmnioxOmnioxSan Carlos, CA, USBiotechest. 2006OmnioxSan Carlos, CA, US · est. 2006

US-based Omniox, a biotech firm, innovates in cancer, cardiovascular disease, and trauma treatment.

Series D · $20.1M7

Jean-François Formela's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Jean-François Formela

Michael D EhlersMichael D EhlersFounder · Intergalactic TherapeuticsH. Martin SeidelH. Martin SeidelFounder · IFM QuattroDan PiacquadioDan PiacquadioFounder · TherapeuticsJohn M LeonardJohn M LeonardBoard Member · Intellia TherapeuticsFrank D. LeeFrank D. LeeBoard Member · Catamaran BioColin FosterColin FosterBoard Member · Ontario Bioscience Industry Organization